Nov 8 (Reuters) - Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period since the administration of the drug in a late-stage trial. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
983.8 USD | -1.02% | +0.57% | +12.01% |
05-22 | Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing | MT |
05-20 | Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.01% | 106B | |
+9.99% | 115B | |
-3.07% | 24.69B | |
-1.16% | 21.97B | |
-5.20% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B | |
+13.63% | 7.76B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron's antibody therapy shows long-term protection against COVID-19